A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 132
- Registration Number
- NCT06563804
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 27
- Registration Number
- NCT06188702
- Locations
- 🇺🇸
Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸NEXT Oncology, Austin, Texas, United States
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 176
- Registration Number
- NCT06162572
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Universitario Virgen de La Victoria, Málaga, Spain
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 136
- Registration Number
- NCT06127407
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇦🇺Sir Charles Gairdner Hospital, Nedlands, Australia
🇧🇷Hospital Das Clínicas Da Ufmg, Belo Horizonte, Brazil
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
- Conditions
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06116136
- Locations
- 🇺🇸
Ocala Oncology Center Pl, Ocala, Florida, United States
🇺🇸Investigative Clinical Research of Indiana, Llc, Noblesville, Indiana, United States
🇦🇺The Queen Elizabeth Hospital, Woodville South, Australia
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05921760
- Locations
- 🇺🇸
UCSF - Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 64
- Registration Number
- NCT05843708
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05159388
- Locations
- 🇪🇸
Hospital Universitario Gregorio, Madrid, Spain
🇦🇺Chris O'Brian Lifehouse, Camperdown, Australia
🇪🇸START, Madrid, Spain